Wednesday, June 25, 2025

Maplight Therapeutics Announces Initiation Of Phase 1 Clinical Trial For Ml-007/Pac, Under Development For Schizophrenia And Alzheimer’s Disease Psychosis

Related stories

Digital Science launches AI writing tools for Overleaf users

Digital Science announced the launch of AI Assist, an...

Centific and Virtue AI team up on responsible AI by Design

This integration delivers 30x faster multimodal protection enabling full-stack...

Vultr Gets $329M to Expand Global AI and Cloud Platform

Vultr secures $329M in credit financing to boost global...

Okta Adds Cross App Access to Secure enterprise AI Agents

Okta launches Cross App Access, a new OAuth-based protocol...

SWARM Biotactics Raises €13M to Advance Bio-Robotics

SWARM Biotactics, developer of bio-robotic systems based on fully...
spot_imgspot_img

MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating CNS disorders, announced initiation of a Phase 1 clinical trial evaluating ML-007/PAC, MapLight’s extended-release fixed-dose combination formulation of the novel, investigational muscarinic agonist ML-007 and a precision-matched peripherally active anticholinergic (PAC). This trial builds upon findings from three prior Phase 1 clinical trials evaluating safety and tolerability of ML-007 co-administered with the PAC.

This four-cohort trial will evaluate the safety, tolerability and pharmacokinetics (PK) of several dose strengths of ML-007/PAC in healthy non-elderly and elderly adults.

Also Read: Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

“We are pleased with the continued progress of our ML-007 clinical development program,” stated Christopher Kroeger, M.D., MBA, Chief Executive Officer and Founder. “We have already evaluated the safety and tolerability profile of ML-007 dosed alone or with the PAC in three clinical trials and observed favorable tolerability results in adults, including in elderly subjects. Data from this fourth Phase 1 trial will inform the ML-007/PAC dosing regimen to bring forward into our planned Phase 2 trials in schizophrenia and Alzheimer’s disease psychosis. We look forward to initiating our first Phase 2 trial of ML-007/PAC in schizophrenia later this year.”

“There still remains a profound level of unmet need in the treatment of schizophrenia with about 60% of patients having only a partial response or no response to treatment,” said John Kane M.D., Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. “The clinical trial evidence for muscarinic receptor agents has been very encouraging, and I believe this new class of agents has the potential to improve the overall treatment of schizophrenia.”

SOURCE: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img